StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

<< Previous

Bullboard Posts

Next >>

Post by MissUniverseon Nov 25, 2020 10:25pm

866 Views

Post# 31976140

$35 billion opportunity

From the document posted today :

"Aristotle as potentially the first multiple, discrete cancer diagnostic test from a single sample of blood, will expand our offering into this commercial framework. This is a $35 billion opportunity and the early diagnosis of cancer via an affordable, patient-friendly test will have an impact on the population level that is simply not achievable now."

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market